new
   Dosage and precautions for Binimetinib
500
Jun 19, 2025

Binimetinib is a targeted therapy drug that is primarily used to treat patients with advanced melanoma who carry specific gene mutations. The drug prevents the growth and spread of diseased cells by inhibiting the activity of MEK protein, and this article will introduce the dosage and precautions of Binimetinib in detail to help patients better use this drug.

Dosage of Binimetinib

Before using Binimetinib, the doctor will develop a personalized treatment plan based on the specific situation of the patient, and the following are the recommended dosages of Binimetinib in general:

Dosage and method of administration

Binimetinib is usually given in the form of oral capsules. The recommended dose for adult patients is 45 mg twice daily every 12 hours. Patients should take the drug on an empty stomach at least 1 hour before or at least 2 hours after a meal. If a dose is missed, it should be retaken as soon as possible, but if it is close to the time of the next dose, skip the missed dose and continue taking the medication at the regular time.

Treatment and adjustments

The treatment cycle of Binimetinib is generally a course of 28 days. Patients should follow the doctor's instructions for the entire course of treatment. During treatment, the doctor regularly assesses the patient's condition and drug reaction, adjusting the dose or stopping the drug if necessary. Patients should not increase or decrease the dose or stop taking the drug on their own, so as not to affect the effect of treatment.

Indications and contraindications for Binimetinib

Before taking the drug, patients and family members should understand what diseases the drug is suitable for and which groups of people are not suitable for use. Here's a detailed explanation of these aspects.

Indications

Binimetinib is primarily indicated for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. This mutation is present in about half of melanoma patients, making Binimetinib one of the preferred treatments for these patients. Before starting treatment, patients need genetic testing to confirm the suitability of Binimetinib.

contraindication

The drug is contraindicated in patients who are allergic to Binimetinib or any of its components. Pregnant women or women planning to become pregnant should avoid Binimetinib, which can cause serious harm to the fetus. Breastfeeding women should also stop breastfeeding, as the drug may be passed to the baby through breast milk. Before using Binimetinib, patients should inform their physician of their complete medical history and current medical condition so that they can make the most appropriate treatment decision.

Medication precautions and daily management

In order to maximize the therapeutic effect of Binimetinib and reduce adverse reactions, patients need to pay attention to the following aspects during medication:

Monitoring and follow-up

During the use of Binimetinib, patients should have regular blood tests and other relevant tests to monitor the effect of the drug and potential side effects. Common monitoring items include liver function, kidney function, electrocardiogram, etc. If abnormalities are found, you should communicate with your doctor in time and adjust your treatment plan if necessary.

Lifestyle adjustments

Patients should pay attention to maintaining good lifestyle habits, such as reasonable diet, moderate exercise, and adequate sleep during the medication. Avoid smoking and alcohol consumption, which are bad habits that may worsen the side effects of the drug, and patients should avoid excessive exposure to sunlight as they may increase the skin's sensitivity to ultraviolet rays than Binimetinib.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Binimetinib(Mektovi)
Adults with advanced or metastatic melanoma with BRAF V600E or V600K mutation.
RELATED ARTICLES
Can pregnant and lactating women use Binimetinib?

Binimetinib, also known as Mektovi, is a drug used to treat certain types of diseases, particularly melanotic...

Thursday, June 19th, 2025, 13:26
Precautions for Binimetinib use

Binimetinib is a targeted therapy drug that is primarily used to treat certain types of diseases, especially those...

Thursday, June 19th, 2025, 13:22
Precautions for the use of Binimetinib(Mektovi)

Binimetinib is a targeted drug used to treat specific types of lesions. This article will introduce the precautions...

Thursday, June 19th, 2025, 11:59
Are the adverse effects of Binimetinib(Mektovi) serious?

The severity of adverse reactions to Binimetinib(Mektovi) varies from individual to individual, but in general, most...

Thursday, June 19th, 2025, 11:32
RELATED MEDICATIONS
Ipilimumab
Unresectable or metastatic melanoma in adult and pediatric patients aged 12...
TOP
1
Encorafenib
For the treatment of melanoma, colorectal cancer (CRC), and non-small cell lung...
TOP
2
Binimetinib
Adults with advanced or metastatic melanoma with BRAF V600E or V600K mutation.
TOP
3
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved